Optimization of inside and outside factors to improve recombinant protein yield in plant

摘要: The use of plant systems as factories for recombinant protein production became a prominent alternative pharmaceutical industries due to their high potential accumulation. In the last decades, application plants has gained more attention, represent an economic strategy that leads levels purified and active proteins sector. Currently, FDA approval first generation produced in carrot cells, taliglucerase alfa, demonstrated cells have significant capacity express complex therapeutic use. Although still technical barriers require improvements future years, optimization upstream downstream components affecting accumulation is considered key feature development new proteins. Therefore, improvement critical features, including transcription, translation post-translational modifications, could make safe economical biopharmaceutical production. Hence, this review, most recent advances influencing processes involved are described. We also discuss how becoming benchmark several biopharmaceuticals.